Related Experiment Videos
[The use of a new balsamic expectorant in bronchopulmonary pathology in children]
Insights
A new anti-inflammatory and expectorant drug, guacetisal (Broncaspin), demonstrated superior clinical effectiveness compared to bromhexine in treating pediatric respiratory inflammation. This study highlights guacetisal as a promising therapeutic option for children.
Area of Science:
- Pharmacology
- Pediatrics
- Respiratory Medicine
Background:
- Respiratory tract inflammation is common in children.
- Existing mucolytic drugs like bromhexine are widely used.
- There is a need for effective anti-inflammatory and expectorant therapies.
Purpose of the Study:
- To compare the therapeutic effectiveness of guacetisal (Broncaspin) with bromhexine.
- To evaluate guacetisal's efficacy in pediatric patients with respiratory inflammation.
Main Methods:
- A comparative study involving 26 pediatric patients.
- Patients were treated at the 1st Pediatrics clinic of Milan University.
- Clinical effectiveness was assessed for both guacetisal and bromhexine.
Main Results:
- Guacetisal (Broncaspin) showed greater clinical effectiveness than bromhexine.
- The study focused on pediatric suspension formulations.
- The new drug proved effective in managing respiratory inflammation.
Conclusions:
- Guacetisal (Broncaspin) is a highly effective therapeutic agent for pediatric respiratory inflammation.
- The drug offers an improved treatment option compared to existing mucolytics.
- Further research may explore broader applications of guacetisal.
Abstract:
The therapeutic effectiveness of a new antiinflammatory-expectorant drug, guacetisal (Broncaspin) has been compared with that of a well known mucolytic, bromexine, already available for therapy, in the paediatric suspension formula. The study was carried out on 26 children in the 1st Paediatrics clinic of Milan University. The children were suffering from inflammation of the respiratory apparatus. It is concluded that the new drug possesses greated clinical effectiveness.